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Abstract: Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to 
radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. 
Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients 
with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and 
safety of this novel treatment and other treatments that are being evaluated in this disease.
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Introduction
There were an estimated 44,670 new cases of thyroid 
cancers in the United States in 2011; medullary thy-
roid cancer (MTC) accounts for about 4% of all new 
cases.1 MTC is considered a neuroendocrine tumor 
as it arises from the parafollicular C cells, which are 
derived from the neural crest. Approximately 80% 
are sporadic and 20% are familial, including Multiple 
Endocrine Neoplasia syndromes (MEN)—MEN 2A 
(60%), MEN 2B (5%) and Familial Medullary Thy-
roid Cancer (FMTC) (35%).2
While most of the familial cases have specifi-
cally rearranged during transfection mutations (RET, 
proto-oncogene RET protein), 30% to 50% of spo-
radic MTC cases may also harbor these mutations 
which may be germ-line or somatic.3 Somatic muta-
tions, those detected only in tumor cells, are seen in 
approximately 50% of sporadic cases while germ line 
mutations, seen in most familial cases, are present in 
6% to 7% of sporadic cases. In RET negative cases, 
a high amount of rat sarcoma gene (RAS) mutations 
(68%) have been identified.3
Management of MTC
MTC is preferably treated with surgical resection. 
Pharmacotherapy is indicated only for cases with 
metastatic or unresectable progressive tumors. 
Various drugs have been tried for the treatment on 
unresectable and metastatic MTC. Conventional che-
motherapy has included bleomycin, anthracyclines 
(especially doxorubicin or Adriamycin) and cisplatin. 
However, chemotherapy has generally been used as 
a last resource in thyroid cancers, although MTC 
has been shown to be somewhat more responsive 
than differentiated or anaplastic thyroid cancers. The 
response rate for MTC has been greater with pulmo-
nary metastases than with locally advanced or bony 
metastasis.6
Novel drugs such as tyrosine kinase inhibitors have 
shown more promise than traditional chemotherapy. 
Vandetanib (ZD6474) has been studied most exten-
sively in clinical trials, and has proven to be a major 
breakthrough in the treatment of advanced meta-
static and progressive MTC. It was approved by the 
United States Food and Drug Administration (FDA) 
in April 2011. However because of possible serious 
side effects, in order for a patient to be approved for 
treatment, a Risk Evaluation and Mitigation Strategy 
(REMS) has been developed to allow the drug to be 
dispensed by only pharmacies and providers that are 
certified through the REMS Vandetanib program.4
Other targeted therapy drugs that are currently in 
clinical trials include other tyrosine kinase inhibitors 
such as carbozantinib (XL184), motesanib, axitinib, 
sorafenib, and sunitinib, and capecitabine, a thymidy-
late synthetase inhibitor.5
Mechanism of Action of Newer Drugs
RET proto-oncogene protein is a trans-membrane 
receptor with an extracellular portion and an intracel-
lular tyrosine kinase domain. Tyrosine kinase activates 
several signaling pathways, including the RAS (pro-
to-oncogene RAS protein), PI3K (phosphoinositide-
3-kinase), JNK (c-Jun N-terminal kinase), ERK5 
(extracellular-signal-regulated kinase), and NFkB 
(nuclear factor κB) pathways. RAS in turn activates 
RAF (proto-oncogene RAF protein), MEK, and ERK 
through phosphorylation (Fig. 1). RAS is a signal 
transduction molecule that belongs to the low molec-
ular weight G protein super family. RAS can bind to 
GTP (guanosine triphosphate) and GDP (guanosine 
diphosphate). Binding to GDP turns it off, while bind-
ing to GTP turns it on. RAS possesses GTPase activ-
ity that converts GTP to GDP and inactivates itself. 
Deregulation of RAS in cancers leads to its continu-
ous activation.
Tyrosine kinase activation in MTC leads to down-
stream activation of signal transducers, leading to 
increased cell growth and proliferation and inhibition 
of apoptosis (Fig. 1). VEGF (vascular endothelial 
Growth factors (RET, EGFR, VEGFR)
Downstream effectors (BRAF, AKT, MEK, MAPK etc.)
Responses at cellular level
Inhibition of receptor tyrosine kinase by vandetanib
Inhibition by novel targeted agents
Angiogenesis, cell growth and proliferation, apoptosis, gene expression, protein synthesis
Figure 1. Targets of MTC treatments.
Abbreviations: AKT, protein kinase B; MAPK, mitogen-activated protein 
kinase; MeK, MAPK or eRK kinase; NFκB, nuclear factor κB; p38 MAPK, 
p38 mitogen-activated protein kinase; PI3K, phosphoinositide-3-kinase; 
RAF, proto-oncogene RAF protein; ReT, proto-oncogene ReT protein.7
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growth factor) activation in VHL (von Hipple Lindau 
syndrome) has also been associated with MTC.7
vandetanib in MTC
Vandetanib acts by RET, VEGF and EGFR inhibition. 
VEGF acts by binding of the VEGF receptor on the 
extracellular surface and promoting angiogenesis 
around the tumor. VEGF inhibition by vandetanib, 
particularly of VEGFR2, which is known to cause 
neovascularization, can thwart tumor growth.
Pharmacokinetics
Vandetanib is an oral tablet taken once daily with a 
half-life of 10 days. Its absorption is not significantly 
affected by food.8 Dose adjustments may be needed 
in subjects with renal impairment. Exposure to the 
drug was not changed in subjects with hepatic impair-
ment, and thus does not necessitate dose adjustments 
for patients with liver disease.9
Vandetanib is partly metabolized by cytochrome 
P450 (CYP) 3A4. Studies have shown decrease in 
blood levels by about 40% during co-administration 
with potent inducers of CYP3A4 (eg, rifampin). The 
increase in exposure of co-administration with inhibi-
tors like itroconazole was found to be low at 9%. It is 
prudent to avoid CYP3A4 inducers with Vandetanib.10 
It should also be avoided with drugs that prolong QT 
interval. Metabolites such as the N-desmethyl and 
N-oxide metabolites and even unchanged Vandetanib 
can be detected in the urine, feces and plasma of 
patients.8
Side effects of vandetanib
Phase 1 trials were first conducted on 77 patients 
in the United States and Australia. These patients 
received different doses of the drug ranging, from 
50 mg to 600 mg. The dosages administered (and 
respective number of patients) were 50 mg (n = 9), 
100 mg (n = 19), 200 mg (n = 8), 300 mg (n = 25), 
500 mg (n = 8) and 600 mg (n = 8).5
Dose limiting toxicities were seen in 6 of the 
16 patients receiving 500 mg and 600 mg doses (3 in 
each). Major side effects included hypertension in 5% 
(n = 4), diarrhea in 5% (n = 4) and rash in 4% (n = 3) 
of patients.
Asymptomatic QTc prolongation occurred at 
100 mg, 300 mg, 600 mg (1 patient each) and 200 mg 
and 500 mg (2 patients each), thus making it less sub-
ject to the amount of dose received.5
In a phase 1 study conducted in Japan, eighteen 
patients were given different doses of the drug, ranging 
from 100 mg to 400 mg. The dosages administered 
(and respective number of patients) were 100 mg 
(n = 3), 200 mg (n = 6), 300 mg (n = 6), and 400 mg 
(n = 3). On completion of two cycles, the dose 
limiting toxicities were hypertension in 17% (n = 3), 
diarrhea in 5% (n = 1), headache in 5% (n = 1), rash in 
5% (n = 1), and alanine aminotransferase increase in 
5% (n = 1) of patients. In another study in Japan, one 
person with 400 mg dose had grade 3 ALT elevation 
and grade 3 hypertension, whereas one person treated 
with 600 mg dose had thrombocytopenia.11 A dose 
of 400 mg per day was considered to exceed the 
maximum tolerated dose (MTD).12
In a study conducted in 36 Chinese subjects,13 42% 
(n = 15) had rash, and 39% (n = 14) had diarrhea. No 
QTc prolongation was seen, whereas ALT elevation 
was seen in 3% (n = 1) of patients.
Other side effects include congestive heart 
failure, nausea, vomiting, cough, nasopharyngitis, 
Table 1. Side effects associated with vandetanib.
Side effect US and Australia  
phase 129
Japan  
phase 112
China  
phase 113
Phase III  
ZETA study22
Meta-analysis with 
300 mg dose14,15
Hypertension 5% 17% 9%
Diarrhea 5% 5% 39% (all grades) 11%
Rash 4% 5% 42% (all grades) 4% 54.3%
QTc prolongation 4% 8%
Alanine aminotransferase  
(ALT) increase
5%
Grade 3 ALT elevation 5% 3%
Thrombocytopenia 5%
QTc prolongation all grades 18%
QTc prolongation grades 3 and 4 12%
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back pain, fatigue, headache, asthenia, anorexia and 
teratogenicity.
QTc prolongation is considered a major side effect 
due to its association with congestive heart failure 
and arrhythmias. In a meta-analysis of 2188 patients 
who received 300 mg Vandetanib as single dose, 
16.4% [95% CI 8.1%–30.4%] had all grade and 
3.7% high grade QTc prolongation. These num-
bers were reported for patients treated for all kinds 
of cancer. However, MTC patients were reported 
to have 18% [95% CI 10.7%–28.6%] all grade and 
12% [95% CI 4.5%–28%] high grade (greater than 
500 ms or symptomatic) QTc prolongation. The 
higher incidence of these events was due to the fact 
that MTC patients took the drug for longer duration. 
The RR of high grade QTc prolongation was found 
to be 3.24 (1.57–6.71) compared to the subjects on 
Vandetanib for cancers other than MTC.14
In a meta-analysis from studies in Pubmed pub-
lished between 1996 and 2011, data from 2961 
patients who received vandetanib 300 mg as a sin-
gle agent were culled. Out of 2961 patients, 46.1% 
[95% confidence interval (CI) 40.6% to 51.8%] 
developed rash (RR.2.43 compared to controls). Of 
the 2961 patients, 261 had MTC, 54.3% [95% CI 
33.4% to 73.8%] of those 261 developed low grade 
rash, and 3.4% [95% CI 1.8%–6.5%] developed high 
grade rash. The endpoints for the study were rash, 
rash/desquamation and acneiform dermatitis.
The percentage of patients developing rash was 
higher in other target therapy drugs: 75.2% [95% CI 
71.3%–78.7%] patients on erlotinib developed low 
grade rash, whereas 9.1% [95% CI 7%–11.7%] devel-
oped a high grade rash. The highest incidence was 
seen with cetuximab, 88.2% [95% CI 84.8%–91%] 
developing a low grade rash and 11.3% [95% 
CI 8.8%–14.3%] developing a high grade rash.15 
Steven-Johnson Syndrome resulting in death was 
also observed. Due to its long half-life, sunscreens and 
protective clothing should be used for four months 
after discontinuation of treatment.16
The prolonged treatment can result in an unusual 
adverse neurological event, reversible cerebral vaso-
constriction syndrome (RCVS), which was reported 
in a patient in his fifties. Thunder-clap headaches 
were first experienced at a time when he was starting 
to urinate. Upon investigation, he was found to have 
multifocal segmental arterial constrictions and a dila-
tion of cerebral arteries on brain angiography consis-
tent with a diagnosis of RCVS. He was successfully 
treated with oral nimodipine.17
Vandetanib was found to be fetotoxic, embryotoxic 
and teratogenic to rats, and while no human data are 
currently available, it is recommended that it should 
be avoided in pregnancy.16
Efficacy of vandetanib in MTC
In general, vandetanib has been found to be more use-
ful in patients in whom metastases progress rapidly 
(in less than 12 months) and diffusely.17 The risk of 
presenting with lymph node and distant metastases 
increases in patients with sporadic medullary thyroid 
cancer with three or four risk allele mutations of RET, 
stressing the importance of target therapy in such 
patients (OR = 5.84).18 The RET S836S variant in 
particular is associated with early onset and increased 
risk of metastatic disease in patients with hereditary, 
as well as sporadic, MTC.19
Two separate studies with different doses of vande-
tanib were conducted to evaluate its efficacy in MTC. 
Out of the 30 patients who received 300 mg vande-
tanib as a single agent, 30% (n = 6) showed partial 
response, whereas, in 53% (n = 16), the disease was 
found to be stable at 24 weeks. The median duration 
of response at data cut off was 10.2 months and the 
disease control rate was thus 73% (22 of 30).20
Table 2. Efficacy of vandetanib.
Effect Vandetanib22 Placebo22 Vandetanib 300 mg20 Vandetanib 100 mg21
Progression free survival 30.5 months 19.3 months 10.2 months Not determined
Partial response 45% 13% 30% 16%
Stable disease $ 24 weeks 87% 71% 53% 53%
Maintained calcitonin decrease 69% 3% 80% 16%
Maintained carcinoembryonic  
antigen reduction
52% 2% 53% 5%
Pharmacotherapy for medullary thyroid cancer
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Vandetanib given in a dose of 100 mg showed that 
16% (n = 3) [95% confidence interval 3.4–39.6] of the 
total 19 patients (13 males) showed a partial response. 
In 53% (n = 10) patients, the disease remained stable 
over a period of 24 weeks. The overall disease control 
rate was noted to be 68% [95% confidence interval 
43.4–87.4]. Calcitonin and CEA sustained 50% or 
greater decrease in 16% (n = 3) and 5% (n = 1) of 
patients respectively.21
In a phase III registration trial, the estimated 
progression-free survival for the patients treated 
with vandetanib was 30.5 months, compared with 
19.3 months for patients who received placebo. In 
this double-blind randomized control trial of patients 
with locally advanced or metastatic disease, 331 
patients were randomly assigned to receive treatment 
with either vandetanib or placebo. Patients in the 
placebo arm found to have disease progression were 
allowed to opt for vandetanib. There were 52 such 
patients, making the true survival improvement rate 
throughout the trial difficult to assess. Vandetanib 
not only improved progression-free survival, but the 
objective response rate was also higher, and several 
other disease-related measures were better in the 
vandetanib arm than in the placebo arm. Since most 
patients in the trial had RET mutations, the effect of 
vandetanib on patients without RET mutations was 
difficult to ascertain.22
Cost of vandetanib
Vandetanib is sold under the brand name Caprelsa, 
developed by AstraZeneca (London, UK). A 30 day 
supply of the drug, 300 mg taken once daily, costs 
approximately $5000 to 10,000 dollars.23
The cost effectiveness of this medication is yet to 
be established. Many studies have used a threshold 
of cost effective ratios of below $50,000 to $100,000 
dollars per quality adjusted life year to demonstrate 
a cost effective treatment.24 Studies on other chronic 
disease conditions may be better comparisons than 
those of aggressive cancer treatments, given that 
MTC can often have an indolent course.
Mechanism of resistance  
to vandetanib and other TKIs
Since these drugs work on various intracellular 
pathways, different molecular mechanisms may 
account for their resistance.
Primary resistance, also known as intrinsic resis-
tance, is host-related, and may be due to pharma-
cokinetic causes. The drug may not be absorbed in 
sufficient quantities, or may be rapidly metabolized 
to inactive compounds. It may also be due to defects 
in the immune system of the body. It is not related to 
the duration of treatment.25
Secondary, or acquired resistance, tends to occur 
after prolonged treatment. The cancer cells may 
become resistant with continued exposure to drugs 
due to the generation of new clone cells that contain 
genetic alterations. Due to this instability, they can 
find an alternative pathway which helps them survive 
and multiply even in the presence of the drug. For 
example, a previous study demonstrated that muta-
tion of tyrosine 806 to cysteine (Y806C) induced 
RET kinase resistance to ZD 6474.26
Other drugs for treatment of MTC
Tyrosine kinase inhibitors sorafenib and sunitnib are 
currently available for treatment of other solid cancers. 
They have been tried for patients with MTC and have 
shown some efficacy. However, they are not curative 
and have not been shown to improve survival rates. 
Table 3. Current studies of new agents in the treatment of MTC.
Title Status Phase
SOM230 alone or in combination with RAD001 in patients with  
medullary thyroid CANCeR
Recruiting 2
An initial study of Lithium in patients with medullary thyroid cancer Recruiting 2
Imatinib in combination with dacarbazine and capecitabine in medullary  
thyroid cancer
Active not  
recruiting
1
A targeted phase I/II study of ZD6474 (vandetanib) plus the proteosome  
inhibitor bortezomib (velcade) in adults with solid tumors with a focus on  
hereditary or sporadic, locally advanced or metastatic medullary thyroid cancer
Active not  
recruiting
1/2
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Motesanib, cabozantinib, a multi-kinase inhibitor, 
and axitinib have also been tried for metastatic MTC, 
resulting in a partial response or stable disease state. 
Clinical trials are yet to be done for bortezomib 
(proteasome inhibitor), valproic acid (histone 
deacetylase inhibitor), capecitabine (5-FU prodrug), 
indomethacin (a well-known non-steroidal anti-
inflammatory), cardiac natriuretic hormones, and an 
extract of the plant cautleya gracilis. Various other 
drugs are in clinical trials and are being evaluated 
for their efficacy and safety in the treatment of MTC. 
These include phase III clinical trials in subjects with 
locally advanced unresectable or metastatic MTC. The 
trials were designed to evaluate the progression-free 
survival in patients receiving cabozantinib compared 
to placebo.28 This study evaluated 330 patients with 
progressive MTC who were randomized to receive 
cabozantinib or placebo. Although the progression 
free survival favored the cabozantinib group 
(11.2 vs. 4 months P , 0.0001), there was no statistical 
difference in overall survival.29 Phase II clinical trials 
are being undertaken for lithium carbonate, SOM 230 
with or without RAD001, imatinib with dacarbazine 
and capecitabine and Vandetanib plus bortezomib 
(Table 3).30
Conclusion
Tyrosine kinase inhibitors have shown promise in 
the treatment of metastatic MTC, which has rein-
vigorated research interest in this area. While RET 
mutations are well described in MTC, new discov-
eries at the molecular level are providing novel tar-
gets for unconventional compounds. In the authors’ 
institution, patients with metastatic medullary thyroid 
cancer are divided into different categories including 
those who have a poor performance status, those with 
a good performance status but stable disease, and 
those with a good performance status and progressive 
or symptomatic disease. It is only the latter group that 
is offered treatment with vandetanib and care is made 
to look for side effects. Performance status can be 
measured using the Eastern Co-operative Oncology 
Group (ECOG) scale (Table 4). The management of 
these side effects is discussed below.
Skin toxicities are managed with the assistance of an 
experienced dermato-oncologist with topical antibiotic 
and if needed, steroid creams or systemic tetracyclines 
or macrolide antibiotics. If these are not effective then 
the medication is withheld until toxicities resolve and 
the medication is restarted at a lower dose.
The authors’ management of QTc prolongation 
involves avoiding the use of vandetanib in patients 
who have a history of QTc prolongation or Torsades de 
Pointes, or who have a baseline QTc interval of greater 
than 450 ms. ECG’s should be obtained at 2–4 weeks 
and 8–12 weeks and then every 3 months while taking 
the medication. Medications that prolong the QTc inter-
val should be avoided. If the QTc interval is prolonged 
to greater than 500 ms while taking the medication, 
vandetanib should be held until the QTc interval falls to 
less than 450 ms and vandetanib can then be restarted at 
a lower dose. If more than 2 dose reductions are needed 
then the medication should not be continued.
Hypertension is a common side effect of many 
tyrosine kinase inhibitors and occurs in 32% of 
patients with MTC taking vandetanib. 8.8% of 
patients develop high grade hypertension.31
In the authors’ institution, hypertension is man-
aged using an angiotensin converting enzyme inhibi-
tor (ACE) or beta blocker for non-black patients and 
a calcium channel blocker for black patients. If the 
blood pressures remain elevated then combinations 
of anti-hypertensives are used together with consulta-
tion with hypertensive specialists. If this along with 
dose reductions do not control blood pressure levels, 
then vandetanib should be discontinued.
Table 4. eCOG performance status.
ECOG performance  
status
Definition Ability to take systemic 
treatment
0 No symptoms Yes
1 Symptomatic but able to maintain activities of daily living Yes
2 Symptoms keep subject in bed less than 50% of the day Yes
3 Symptoms keep subject in bed more than 50% of the day No
4 Symptoms keep subject in bed 100% of the day No
Pharmacotherapy for medullary thyroid cancer
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